UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 State ...

Dyadic International, Inc. (NASDAQ:DYAI) Q2 2020 Earnings Conference Call August 13, 2020 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Matthew Jones - Managing Director, Business Development and Licensing Ronen Tchelet - Vice President of Research and Business Development Conference Call Participants John Vandermosten - Zacks Investment Research Ahu Demir - NOBLE Capital Markets, Inc. Operator Good evening, ladies and gentlemen, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 State or O ...

Dyadic International, Inc. (NASDAQ:DYAI) Q1 2020 Earnings Conference Call May 14, 2020 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President and CEO Ronen Tchelet - VP, Research and Business Development Matthew Jones - MD, Business Development and Licensing Conference Call Participants Luke Smith - Chapin Davis John Vandermosten - Zacks Investment Research Jason Kolbert - Dawson James Ahu Demir - Noble Capital Robert Smith - Center Performance Investing Operator Good evening, ladies an ...

Financial Performance - Total current assets decreased from $35,639,238 as of December 31, 2019, to $32,819,441 as of March 31, 2020, a decline of approximately 8.1%[13] - Research and development revenue for the three months ended March 31, 2020, was $315,372, down from $402,527 for the same period in 2019, representing a decrease of about 21.6%[15] - Total costs and expenses decreased from $2,843,847 in Q1 2019 to $2,697,894 in Q1 2020, a reduction of approximately 5.1%[15] - The net loss for the three months ended March 31, 2020, was $2,214,139, compared to a net loss of $2,175,258 for the same period in 2019, indicating a slight increase in loss of about 1.8%[15] - Cash and cash equivalents at the end of the period were $4,696,831, a decrease from $4,823,544 at the beginning of the period, reflecting a decline of approximately 2.6%[21] - The company reported a basic and diluted net loss per common share of $0.08 for both the three months ended March 31, 2020, and March 31, 2019[15] - Total stockholders' equity decreased from $35,864,471 as of December 31, 2019, to $34,252,271 as of March 31, 2020, a decline of approximately 4.5%[19] - For the three months ended March 31, 2020, the Company's revenue was $315,000, a decrease of approximately 36.5% compared to $496,000 for the same period in 2019[40] - The Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of total revenue for the three months ended March 31, 2020[41] - As of March 31, 2020, accounts receivable totaled $518,601, a decrease from $558,530 as of December 31, 2019[50] - The Company had cash and cash equivalents sufficient to fund operations for at least the next twelve months, but may seek additional funding if necessary[33] - The Company recognized revenue based on a cost-based input method, reflecting actual costs incurred relative to budgeted costs[57] - The allowance for doubtful accounts was zero as of March 31, 2020, indicating that substantially all accounts receivable were current[49] - Research and development costs for the three months ended March 31, 2020, totaled $755,453, compared to $1,081,843 for the same period in 2019, reflecting a decrease of approximately 30%[66] - General and administrative expenses rose by 15.8% to approximately $1,653,000 compared to $1,428,000 for the same period last year, driven by increases in insurance and outside service costs[185] - Interest income decreased by 37.1% to approximately $168,000 compared to $267,000 for the same period in 2019, attributed to lower interest rates on investment grade securities[186] - Net cash used in operating activities for the three months ended March 31, 2020, was approximately $2.0 million, primarily due to the net loss and changes in operating assets and liabilities[191] Research and Development - The company aims to enhance its proprietary C1 technology for the biopharmaceutical industry, focusing on the development of biologic vaccines and drugs[27] - Dyadic has retained co-exclusive rights to the C1 technology for human and animal pharmaceutical applications following the sale of its industrial technology business to DuPont[26] - The company is targeting the development of innovative vaccines, drugs, biosimilars, and biobetters using its C1 technology[27] - The Company has no pharmaceutical products approved for sale and generates revenue solely from research collaborations and government grants[55] - The Company has established a deferred revenue from licensing agreements for upfront fees received prior to technology transfer[63] - The Company has not disclosed the value of unsatisfied performance obligations for contracts with an original expected length of one year or less[64] - Dyadic entered into a strategic research collaboration with BDI, committing EUR €1 million for the development of C1 based product candidates[94] - BDI is obligated to spend a minimum of EUR €936,000 over two years on the research project under the RSA[94] - The company extended its research contract with VTT for a total of EUR €2.52 million over three years to develop the C1 fungal expression system[113] - An additional EUR €690,000 was added to the VTT contract to reinforce glycoengineering work, with further expansion of EUR €700,000 announced on March 23, 2020[113] - Dyadic has entered into a funded collaboration with a top four animal health company for a feasibility study on producing two proteins using the C1 platform, with three of the top four animal health companies currently funding research programs[140] - A new feasibility study has been initiated with the University of Oslo focused on influenza vaccine development[142] - The collaboration with the Israel Institute for Biological Research has expanded to explore the potential of C1 for expressing gene sequences into rVaccine candidates and monoclonal antibodies to combat COVID-19[143] - Dyadic's C1 platform is being utilized for vaccine candidates developed by Ufovax and scientists from the EU ZAPI initiative[144] COVID-19 Impact - The Company is actively pursuing COVID-19 related vaccine and antibody opportunities, collaborating with various research institutions[32] - The Company is competing with more experienced companies for grants or funding related to its COVID-19 initiatives, with no assurance of success[32] - The ongoing COVID-19 pandemic has significantly impacted business operations, potentially affecting research projects and financial conditions[206] - The Company is currently exploring several COVID-19 related vaccine and antibody opportunities[209] - There is no assurance that the C1 technology will successfully produce a vaccine or antibody that enters clinical trials[209] - The Company has not secured any grants or funding from its proposals related to COVID-19[209] - There is uncertainty regarding the ability to obtain governmental safety and regulatory approvals for any products developed[209] Stock and Equity - As of March 31, 2020, the company had 4,663,390 stock options outstanding, with a weighted average exercise price of $2.44 and an aggregate intrinsic value of $13,017,190[116] - Total non-cash stock option compensation expense for the three months ended March 31, 2020, was $426,939, compared to $309,563 for the same period in 2019, reflecting an increase of approximately 37.9%[126] - The company issued 100,000 shares of common stock due to the exercise of stock options at a weighted average issue price of $1.78 per share during the three months ended March 31, 2020[127] - The company recognized share-based compensation expenses of $380,251 in general and administrative expenses and $46,688 in research and development expenses for the three months ended March 31, 2020[126] - The company has retained co-exclusive rights to the C1 technology for human and animal pharmaceutical applications after the DuPont Transaction, which was valued at $75 million[136] - Dyadic will receive a 20% equity interest in Novovet under the Luina Bio Sub-License Agreement, contingent on future net sales and revenue[99] - The Alphazyme Sub-License Agreement includes a 7.5% ownership interest for Dyadic upon successful technology transfer, with additional milestone payments[105] Financial Position - As of March 31, 2020, deferred tax assets were approximately $9.6 million, with a 100% valuation allowance established due to operating losses[75] - The Company reported cash and cash equivalents of $4,696,831 as of March 31, 2020, with total investments amounting to $33,673,423[86] - The company does not consider any of its investments to be other-than-temporarily impaired as of March 31, 2020[90] - As of March 31, 2020, the company held 12,253,502 shares of common stock in treasury, at a cost of approximately $18.9 million[129] - The expected stock price volatility for options granted during the three months ended March 31, 2020, ranged from 39.94% to 51.22%[123] - The company continues to monitor the potential effects of the COVID-19 pandemic on its financial condition and operations[132] - The Company expects to receive a remaining tax refund of approximately $0.5 million in 2020 pursuant to the CARES Act[74]

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share DYAI The NASDAQ Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commiss ...

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2019 Earnings Conference Call November 13, 2019 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Matthew Jones - Chief Commercial Officer Ronen Tchelet - Chief Scientific Officer Conference Call Participants Jason Kolbert - Dawson James John Vandermosten - Zacks SCR Ahu Demir - Noble Capital Markets Barry Kitt - Pinnacle Fund Dick Williams - Williams Research Group Operator Good evening, ladi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share DYAI The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ ...

Dyadic International, Inc. (NASDAQ:DYAI) Q2 2019 Earnings Conference Call August 13, 2019 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President and CEO Matthew Jones - Chief Commercial Officer Ronen Tchelet - Chief Scientific Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Ahu Demir - Noble Capital Dick Williams - Williams Research Group Operator Good afternoon, ladies and gentlemen, and thank you for holding. Welcome to Dyadic International's Seco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC® DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) State or Other Jurisdi ...